Agilent Technologies Inc (NYSE:A) CEO Michael R. Mcmullen sold 21,850 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $72.50, for a total transaction of $1,584,125.00. Following the completion of the transaction, the chief executive officer now owns 324,687 shares in the company, valued at approximately $23,539,807.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Agilent Technologies Inc (NYSE A) traded up $0.13 during mid-day trading on Friday, reaching $72.19. The company had a trading volume of 1,828,300 shares, compared to its average volume of 1,846,967. Agilent Technologies Inc has a 12 month low of $47.05 and a 12 month high of $72.50. The stock has a market capitalization of $23,450.00, a price-to-earnings ratio of 34.54, a price-to-earnings-growth ratio of 2.18 and a beta of 1.28. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.30 and a quick ratio of 2.85.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Agilent Technologies had a return on equity of 16.95% and a net margin of 15.30%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the firm posted $0.59 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. research analysts predict that Agilent Technologies Inc will post 2.58 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd will be paid a $0.149 dividend. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.13. The ex-dividend date is Friday, December 29th. This represents a $0.60 dividend on an annualized basis and a yield of 0.83%. Agilent Technologies’s dividend payout ratio (DPR) is presently 28.71%.

Several research analysts have recently issued reports on the stock. Robert W. Baird restated a “buy” rating and issued a $76.00 target price on shares of Agilent Technologies in a report on Thursday. Goldman Sachs Group restated a “neutral” rating and issued a $68.00 target price on shares of Agilent Technologies in a report on Tuesday, September 26th. Cowen restated a “hold” rating and issued a $65.00 target price on shares of Agilent Technologies in a report on Thursday, September 28th. Evercore ISI assumed coverage on shares of Agilent Technologies in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $75.00 target price on the stock. Finally, Barclays restated a “buy” rating and issued a $74.00 target price on shares of Agilent Technologies in a report on Monday, January 8th. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $69.25.

A number of hedge funds have recently made changes to their positions in A. Advisor Group Inc. lifted its position in Agilent Technologies by 0.3% during the second quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock valued at $235,000 after buying an additional 10 shares during the period. Veritable L.P. lifted its position in Agilent Technologies by 0.4% during the second quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock valued at $646,000 after buying an additional 40 shares during the period. Balentine LLC lifted its position in Agilent Technologies by 2.9% during the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after buying an additional 50 shares during the period. Kingfisher Capital LLC lifted its position in Agilent Technologies by 0.3% during the second quarter. Kingfisher Capital LLC now owns 22,643 shares of the medical research company’s stock valued at $1,343,000 after buying an additional 58 shares during the period. Finally, Quadrant Capital Group LLC lifted its position in Agilent Technologies by 2.4% during the second quarter. Quadrant Capital Group LLC now owns 5,604 shares of the medical research company’s stock valued at $317,000 after buying an additional 134 shares during the period.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/01/19/agilent-technologies-inc-a-ceo-michael-r-mcmullen-sells-21850-shares.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Insider Buying and Selling by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.